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Longer Repolarization in the Epicardium
at the Right Ventricular Outflow Tract Causes Type 1
Electrocardiogram in Patients With Brugada Syndrome
Satoshi Nagase, MD, Kengo Fukushima Kusano, MD, Hiroshi Morita, MD, Nobuhiro Nishii, MD,
Kimikazu Banba, MD, Atsuyuki Watanabe, MD, Shigeki Hiramatsu, MD, Kazufumi Nakamura, MD,
Satoru Sakuragi, MD, Tohru Ohe, MD
Okayama, Japan
Objectives We examined the relationship between repolarization abnormality and coved-type ST-segment elevation with
terminal inverted T-wave (type 1 electrocardiogram [ECG]) in patients with Brugada syndrome (BrS).
Background Recent experimental studies have suggested that accentuation of the right ventricular action potential (AP)
notch preferentially prolongs epicardial AP causing inversion of the T-wave.
Methods In 19 patients with BrS and 3 control subjects, activation-recovery intervals (ARIs) and repolarization times (RTs)
in the epicardium and endocardium were directly examined with the use of local unipolar electrograms at the
right ventricular outflow tract. Surface ECG, ARI, and RT were examined before and after administration of
pilsicainide.
Results Type 1 ECG was observed in 10 of the 19 BrS patients before the administration of pilsicainide and in all of the
19 patients after the administration of pilsicainide. We found that ARI and RT in the epicardium were shorter
than those in the endocardium in all 9 BrS patients without type 1 ECG under baseline conditions and in all con-
trol subjects regardless of pilsicainide administration. However, longer epicardial ARI than endocardial ARI was
observed in 8 of the 10 BrS patients manifesting type 1 ECG under baseline conditions and in all of the BrS pa-
tients after the administration of pilsicainide. Also, epicardial RT was longer than endocardial RT in all patients
manifesting type 1 ECG regardless of pilsicainide administration.
Conclusions Our data provide support for the hypothesis that the negative T-wave associated with type 1 BrS ECG is due to a
preferential prolongation of the epicardial AP secondary to accentuation of the AP notch in the region of the
right ventricular outflow tract. (J Am Coll Cardiol 2008;51:1154–61) © 2008 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.10.059S
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prugada syndrome (BrS) is characterized by ST-segment
levation in right precordial leads and an episode of ventricular
brillation (VF) (1,2). Recent experimental studies have sug-
ested that a prominent transient outward current-mediated
ction potential notch in epicardial cells, but not that in
ndocardial cells, creates a transmural voltage gradients and
hus causes ST-segment elevation (3). When epicardial repo-
arization precedes endocardial repolarization, the T-wave
emains positive. In this condition, saddleback-type electrocar-
iogram (ECG) was observed. Further accentuation of the
otch leads to preferential prolongation of the epicardial action
otential, which results in the development of coved-type
rom the Departments of Cardiovascular Medicine, Okayama University Graduate
chool of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.p
Manuscript received May 4, 2007; revised manuscript received September 24, 2007,
ccepted October 17, 2007.T-segment elevation and terminal inverted T-wave (type 1
CG) in right precordial leads in BrS (4–6). A definitive
iagnosis of BrS is made when a type 1 ECG is observed, and
ype 1 ECG can be unmasked by sodium channel blockers
ven in symptomatic patients (2,7–9).
See page 1176
In a clinical study, Kurita et al. (10) found a prominent
ction potential notch and prolongation of repolarization in
he epicardium but not in the endocardium at the right
entricular outflow tract (RVOT) in 3 patients with BrS
uring open chest surgery with monophasic action potential
ecording.
Prolongation of the QT interval also has been reported in
atients with BrS. Prolongation of the QT interval is more
rominent in right precordial leads than in left precordial
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March 25, 2008:1154–61 Longer Repolarization in Brugada Syndromeeads, presumably because of a preferential prolongation of
ction potential duration in the right ventricular epicardium
econdary to accentuation of the action potential notch
11,12). An overlap between BrS and long-QT syndrome
lso has been reported (13,14).
Recent studies have demonstrated that the activation-recovery
nterval (ARI) approximates the action potential duration at
ach site in several experimental and clinical studies (15,16).
ecently, we have reported successful recording of an epicardial
lectrogram at the RVOT in patients with BrS by the use of an
lectrical guide wire introduced into the conus branch of the
ight coronary artery (17).
Accordingly, we measured epicardial and endocardial ARIs
irectly at the RVOT to examine the epicardial and endocar-
ial action potentials in patients with BrS, and we demon-
trated a correlation between morphology of surface ECG and
RI in the epicardium and endocardium. We also measured
ctivation time (AT) and repolarization time (RT). Because
he administration of a sodium channel blocker can unmask
ype 1 ECG in right precordial leads, we examined the effect of
njection of a pure sodium channel blocker, pilsicainide, on the
orphology of surface ECG and each parameter in the
picardium and endocardium in patients with BrS.
ethods
atients. Nineteen patients with BrS and 3 control
ubjects were included in this study. We defined BrS as
atient Characteristics
Table 1 Patient Characteristics
Patient # Age, yrs Gender
Brugada syndrome 1 48 Male
2 33 Male
3 45 Male
4 55 Male
5 48 Male
6 47 Male
7 47 Male
8 50 Male
9 62 Male
10 42 Male
11 40 Male
12 72 Male
13 56 Male
14 44 Male
15 46 Male
16 51 Male
17 62 Male
18 44 Male
19 43 Male
Control subject 1 53 Male
2 57 Male
3 28 MaleES  programmed electrical stimulation; NA  not available; SD  sudden death; VF  ventricular fibrhe manifestation of type 1
CG, which is characterized by
coved-type ST-segment ele-
ation 2 mm (0.2 mV) fol-
owed by a negative T-wave in
eads V1 or V2 at the third or
ourth intercostal space in the
resence or absence of a class
C antiarrhythmic drug (pilsic-
inide) (2). This type of repo-
arization pattern was described
reviously by Wilde et al. (7).
atient characteristics are
hown in Table 1.
Routine examinations, includ-
ng cardiac echocardiography,
oronary angiography, right and
eft ventriculography, and radio-
ucleography, showed no evi-
ence of structural heart disease
n any of the patients. One of the
ontrol subjects was diagnosed as
aving idiopathic VF with no
T-segment elevation, and the
emaining 2 control subjects had
ncomplete right bundle branch
lock in surface ECG. Brugada-
ype ECG was not observed under baseline conditions or
fter pilsicainide injection in any of the control subjects.
Abbreviations
and Acronyms
ARI  activation-recovery
interval
ARIc  activation-recovery
interval corrected for heart
rate
AT  activation time
BrS  Brugada syndrome
ECG  electrocardiogram
RT  repolarization time
RVOT  right ventricular
outflow tract
V1(3ics)  surface ECG
lead V1 at the third
intercostal space
V2(3ics)  surface ECG
lead V2 at the third
intercostal space
V1(4ics)  surface ECG
lead V1 at the fourth
intercostal space
V2(4ics)  surface ECG
lead V2 at the fourth
intercostal space
VF  ventricular fibrillation
inical Symptom
Induced
VF by PES
Family
History of SD
SCN5A
Mutation
VF   
VF   
Syncope   
VF   
VF   
VF   
Syncope   
VF   
No   
No   
No   
No   
No   
No   
No   
No   
No   
No   
No   
VF   NA
No   NA
No   illation.Cl
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Longer Repolarization in Brugada Syndrome March 25, 2008:1154–61lectrophysiologic study. A maximum of 3 ventricular
xtrastimuli were delivered from right ventricular apex and
VOT unless VF was induced at a previous step in all
atients with BrS and control subjects. We induced VF by
rogrammed electrical stimulation in 11 patients with BrS
ut was not induced in control subjects. We examined
RIs, ATs, and RTs in the epicardium and endocardium
imultaneously using local unipolar electrograms at the
VOT with a 0.05- to 400-Hz bandwidth under baseline
onditions and after intravenous injection of a pure sodium
hannel blocker, pilsicainide, at a dose of 1 mg/kg during a
-min period. The ARI and RT were corrected for heart
ate by Bazett’s formula and named ARIc and RTc (18). To
ecord the epicardial electrogram directly, we introduced an
lectrical guidewire (Flo Wire, Cardiometrics, Mountain
iew, California) into the conus branch of the right
oronary artery, which runs on the surface of the free wall at
he RVOT (Fig. 1). The epicardial mapping has been
escribed in detail previously (17). A local unipolar electro-
ram at the endocardium was recorded by a quadripolar 6-F
eflectable catheter positioned at the endocardium at the
ree wall at the RVOT. We defined ARI as the interval
etween times of minimum derivative of the QRS and
aximum derivative of the T-wave in a unipolar electro-
ram (15). We defined AT as the interval between the
eginning of the surface QRS complex and minimum
erivative of the QRS. We defined RT as the interval
etween the beginning of the surface QRS complex and
aximum derivative of the T-wave (Fig. 2). For analysis of
RI, AT, and RT, the analog data were digitized at a
ampling rate of 1,000 samples/s and stored on a floppy
isk, then transferred to a personal computer with the
nalysis program developed by our institution (S.H.). The
ifference in ARI/ARIc was defined as the value of epicar-
ial ARI/ARIc minus endocardial ARI/ARIc. Accordingly,
Figure 1 Catheter Position
Fluoroscopic right anterior oblique (RAO) (A) and left anterior oblique (LAO) (B) vie
epicardial mapping (RVOT-epi), as well as the quadripolar catheter at the endocardf epicardial ARI is longer than endocardial ARI, theifference in ARI is positive. The difference in AT and
T/RTc were defined as epicardial AT minus endocardial
T and epicardial RT/RTc minus endocardial RT/RTc.
ecause recent studies have shown that the site of maximum
T-segment elevation in body surface ECG coincides with
he RVOT and because the RVOT corresponds to leads V1
nd V2 at the third intercostal space (3ics), surface ECG
lso was recorded at the 3ics in leads V1 and V2 in addition
o the standard V1 and V2 at the fourth intercostal space
4ics) (19–21). We defined that type 1 ECG was present if
the position of the electrical guidewire for
f the free wall at the RVOT for endocardial mapping (RVOT-endo).
Figure 2 Example of Surface Electrocardiograms (II, V2, and
V5) and Intracardiac Unipolar Electrogram at the RVOT
Activation-recovery interval (ARI), repolarization time (RT), and
activation time (AT) were measured at the right ventricular outflow tract (RVOT).ws of
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March 25, 2008:1154–61 Longer Repolarization in Brugada Syndromeype 1 ECG was recorded in more than one of the surface
CG leads, including V1(3ics), V2(3ics), V1(4ics), or
2(4ics). Electrophysiologic study and genetic analysis were
erformed according to the protocol approved by the Ethics
ommittee of Okayama University Graduate School of
edicine, Dentistry, and Pharmaceutical Sciences. Written
nformed consent was obtained from all patients.
utation analysis of SCN5A. Genetic screening was
erformed in all patients with BrS. All 28 exons of SCN5A
ere amplified with polymerase chain reaction from de-
xyribonucleic acid isolated from peripheral leukocytes us-
ng intronic primers. Polymerase chain reaction products
ere subjected to direct sequencing of all coding regions.
tatistical analysis. Quantitative values are expressed as
eans  standard deviation values. We compared ARI/
RIc, RT/RTc, and AT before and after the administration
f pilsicainide administration by means of a paired t test.
ifferences in ARI/ARIc, RT/RTc, and AT before and
fter pilsicainide administration also were compared by
eans of a paired t test. We used the Student t test to
ompare ARI/ARIc, RT/RTc, and AT between the epicar-
ium and endocardium. Student’s t test also was used for
omparison of differences in ARI/ARIc, RT/RTc, and AT
etween BrS patients and control subjects. Differences in
RI/ARIc between SCN5A mutation careers and nonca-
eers also were compared by means of a Student t test. A
alue of p  0.05 was considered statistically significant.
esults
igure 3 shows representative surface ECGs and unipolar
lectrograms in a control subject (Fig. 3A) and 2 patients
ith BrS (Figs. 3B and 3C) under baseline conditions and
fter pilsicainide injection.
As shown in Figure 3A, Brugada-type ECG was not
bserved under baseline conditions or after pilsicainide injec-
ion in the control subject (Patient #3). Epicardial ARI was
lways shorter than endocardial ARI both before and after
ilsicainide injection. The epicardial ARI was 23 ms shorter
han the endocardial ARI under baseline conditions and was
2 ms shorter than the endocardial ARI after pilsicainide
njection. The difference in ARI was thus defined as –23 ms
efore and –22 ms after pilsicainide injection.
As shown in Figure 3B, type 1 ECG was observed in lead
2(3ics), and epicardial ARI (239 ms) was longer than
ndocardial ARI (187 ms), and the difference in ARI was
herefore defined as 52 ms under baseline conditions in
he Brugada patient (Patient #1).
As shown in Figure 3C, type 1 ECG was not observed in
ll of the surface ECG leads, and epicardial ARI (210 ms)
as shorter than endocardial ARI (248 ms) under baseline
onditions in the Brugada patient (Patient #16). The
picardial ARI was 38 ms shorter than the endocardial ARI,
nd the difference in ARI was thus defined as –38 ms.
owever, after administration of pilsicainide, the epicardial
RI, but not the endocardial ARI, was markedly prolongedFigure 3 Patient Examples
Representative surface ECGs and unipolar electrograms in a control subject
(A) and in 2 patients with Brugada syndrome (B and C) under baseline condi-
tions (left panels) and after pilsicainide administration (right panels). (A) Bru-
gada-type ECG was not observed in surface ECGs. Under baseline conditions,
the epicardial ARI (221 ms) was shorter than the endocardial ARI (244 ms).
After the administration of pilsicainide, the epicardial ARI (208 ms) was still
shorter than the endocardial ARI (230 ms). (B) Under baseline conditions, type
1 ECG was observed in lead V2(3ics) (), and the epicardial ARI (239 ms) was
longer than the endocardial ARI (187 ms). After the administration of pilsicain-
ide, type 1 ECG was still observed in lead V2(3ics) (), and epicardial ARI (222
ms) was longer than endocardial ARI (190 ms). (C) Under baseline conditions,
type 1 ECG was not observed in any of the surface ECG leads, and the epicar-
dial ARI (210 ms) was shorter than endocardial ARI (248 ms). However, after
administration of pilsicainide, the epicardial ARI, but not the endocardial ARI,
was markedly prolonged (260 ms), and type 1 ECG appeared in lead V2(3ics)
(). The epicardial ARI was 18 ms longer than the endocardial ARI (242 ms).
Numbers indicate ARI. ARI  activation-recovery interval; ECG  electrocardio-
gram; RVOT-epi  uniploar electrogram of the epicardium at the right ventricu-
lar outflow tract; RVOT-endo  uniploar electrogram of the endocardium at the
right ventricular outflow tract;   type 1 ECG.
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Longer Repolarization in Brugada Syndrome March 25, 2008:1154–61260 ms). Type 1 ECG appeared after pilsicainide admin-
stration in lead V2(3ics). The epicardial ARI was 18 ms
onger than the endocardial ARI, and the difference in ARI
as thus defined as 18 ms.
Table 2 shows electrophysiologic data in all patients. Type 1
CG was observed in 10 of the 19 patients with BrS under
aseline conditions and in all of the patients with BrS after
dministration of pilsicainide. Pilsicainide administration sig-
ificantly prolonged epicardial ARI/ARIc from 222.9  16.3
s/248.0  22.2 ms to 235.1  22.2 ms/268.9  24.9 ms
p  0.001/p  0.001) but did not prolong endocardial
RI/ARIc (219.3  17.0 ms/243.6  18.1 ms vs. 213.6 
7.4 ms/244.3  18.7 ms; p  NS/p  NS) in patients with
rS. And epicardial ARI/ARIc were significantly longer than
ndocardial ARI/ARIc after pilsicainide administration in BrS
p  0.01/p  0.01). Pilsicainide administration significantly
rolonged the difference in ARI/ARIc from 3.6  22.0
s/4.4  24.6 ms to 21.5  13.7 ms/24.6  15.7 ms
p  0.001/p  0.001) in patients with BrS.
Figure 4 shows the relationship between differences in
RIc, RTc, and AT and appearance of type 1 ECG. In
ll control subjects, the epicardial ARIc was always
horter than the endocardial ARIc, and the difference in
RIc was always 0 ms. Type 1 ECG was not observed
nder baseline conditions and also after pilsicainide
dministration in the control subjects. However, under
aseline conditions, all nine BrS patients without type 1
CG had a difference in ARIc of 0 ms, and 8 of 10 BrS
atients with type 1 ECG had a difference in ARIc of
ore than 0 ms. The difference in ARIc with type 1
CG was significantly larger than that without type 1
CG under baseline conditions (p  0.0001). After
dministration of pilsicainide, type 1 ECG appeared and
he difference in ARIc was more than 0 ms in all patients
ith BrS (Fig. 4A). Epicardial RTc was always longer
han endocardial RTc in patients manifesting type 1
CG regardless of pilsicainide administration. The dif-
erence in RTc with type 1 ECG was significantly larger
han that without type 1 ECG in BrS patients under
aseline conditions (p  0.00001) (Fig. 4B). The differ-
nce in AT with type 1 ECG was also significantly larger
han that without type 1 ECG in BrS patients under
aseline conditions (p  0.05) (Fig. 4C). However, the
ifference in AT was a less critical as a factor determining
ype 1 ECG than was the difference in RTc or ARIc.
ccordingly, type 1 ECG was closely related to the
rolongation of repolarization in the epicardium compared
o that in the endocardium.
Mutation of the SCN5A gene was identified in 4 of the
9 patients (Patient #1, R282H; Patient #2, IVS211 ga;
atient #3, R1913C; Patient #9, Y416C) with BrS. The
ifferences in ARI/ARIc and RT/RTc between epicardium
nd endocardium were significantly larger in 4 SCN5A
utation carriers than that in 15 noncarriers before pilsic-
inide administration (Figs. 4A and 4B). However, the El
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inide was administered.
iscussion
ain findings of the study. The results of this study show
hat type 1 ECG is closely related to the prolongation of
epolarization in the epicardium compared with that in the
ndocardium in BrS. The administration of pilsicainide, a
ure sodium channel blocker, exaggerated the prolongation
f repolarization in the epicardium, which contributed to
he development of type 1 ECG in BrS. In the control
ubjects, ARI/ARIc and RT/RTc in the epicardium were
lways shorter than those in the endocardium regardless of
ilsicainide administration.
echanism of type 1 ECG. Recent experimental studies
ave suggested that a prominent transient outward
urrent-mediated action potential notch during phase 1
epolarization in the epicardium, but not in the endo-
ardium, gives rise to a transmural voltage gradient,
hich is responsible for prominent ST-segment elevation
n BrS. When epicardial repolarization precedes endocar-
ial repolarization, the T-wave remains positive. How-
ver, further accentuation of the notch causes longer
ction potential duration in the epicardium than in the
ndocardium due to a delay in the onset of the second
pstroke and phase 3, which results in a coved-type
T-segment elevation and inversion of the T-wave (type
ECG) (4–6). In the present study, we were able to
ecord epicardial and endocardial unipolar electrograms
imultaneously in all patients. And we could demonstrate
onger action potential duration in the epicardium than
hat in the endocardium using ARI and RT, and we
ound a close correlation between prolongation of repo-
arization in the epicardium and type 1 ECG.
Prolongation of RT in the epicardium could be also
xplained by conduction slowing at the RVOT instead of
ransmural repolarization differences. Delayed activation
t the epicardial cell could result in later termination of
epolarization than endocardial cell, which could demon-
trate terminal inverted T-wave (22,23). Coronel et al.
eported that minor transmural gradient in RT causes
ynamic T-wave change and that activation delay is also
n important factor in determining transmural gradient
n RT (24). In the present study, we also showed the mild
rolongation of AT in the epicardium in patients with
ype 1 ECG. However, the difference in AT was a less
ritical as a factor determining type 1 ECG than was the
ifference in RT/RTc or ARI/ARIc in our study.
CN5A mutation. It has been reported that mutation of
he SCN5A gene was identified in approximately 10% to
0% of patients with BrS (2,25). In this study, SCN5A
utation was identified in 4 of the 19 patients with BrS.
he differences in ARI/ARIc and RT/RTc between the
picardium and endocardium were significantly larger inFigure 4 Relationship Between Appearance
of Type 1 ECG and Each Parameter
Relationship between appearance of type 1 electrocardiogram (ECG) and
differences in activation-recovery interval corrected for heart rate (ARIc) (A),
repolarization time corrected for heart rate (RTc) (B), and activation time
(AT) (C) in control subjects (Control) and in patients with Brugada syndrome
(Brugada) under baseline conditions (Baseline) and after the administration
of pilsicainide (After Pilsicainide). (A) Type 1 ECG was closely related to the
prolongation of ARIc in the epicardium compared with that in the endocar-
dium. The difference in ARIc with type 1 ECG was significantly larger than
that without type 1 ECG under baseline conditions (p  0.0001). After the
administration of pilsicainide, type 1 ECG appeared and the difference in
ARIc was more than 0 ms in all patients with Brugada syndrome. (B) Epi-
cardial RTc was always longer than endocardial RTc in patients manifesting
type 1 ECG regardless of pilsicainide administration. The difference in RTc
with type 1 ECG was significantly larger than that without type 1 ECG in Bru-
gada syndrome patients under baseline conditions (p  0.00001). (C) The
difference in AT with type 1 ECG was significantly larger than that without
type 1 ECG in Brugada syndrome patients under baseline conditions (p 
0.05). However, the difference in AT was a less critical factor determining
type 1 ECG than was the difference in RTc or ARIc. Open black circles 
type 1 ECG was recorded in surface ECG without SCN5A mutation; open
blue circles  type 1 ECG was recorded in surface ECG with SCN5A muta-
tion; open diamonds  type 1 ECG was not recorded in surface ECG.CN5A mutation carriers than in noncarriers before the
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atients was small and their clinical backgrounds and
utation sites were heterogeneous, the mechanism under-
ying this phenomenon is unclear.
ilsicainide administration. Pilsicainide administration
eveloped ventricular arrhythmias in 4 patients (Patient #8,
F; Patients #4, #10, and #13, premature ventricular
ontractions; Patient #11, nonsustained polymorphic ven-
ricular tachycardia) (26). However, no difference was ob-
erved in any of the parameters between the patients with
nd without pilsicainide-induced ventricular arrhythmias.
nd the distinctive finding, such as phase 2 re-entry, was
ot apparent in the initiation of ventricular arrhythmia at
he epicardium and endocardium.
tudy limitations. We were able to record electrograms
nly at the site where the conus branch of the right coronary
rtery runs through. Therefore, we could not perform
etailed mapping in the epicardium at the RVOT. We
ttempted to introduce the guidewire into the conus branch
n more than 50 patients with BrS. However, we were able
o successfully introduce the guidewire deeply at the RVOT
n only about 50% patients due to technical problems and
ocation of the conus branch.
Marked shortening of ARI in the epicardium was not
emonstrated under baseline conditions or after pilsicainide
dministration in this study. However, we could not rule out
he possibility of “loss of dome” configuration of action
otential in another epicardial site, because detailed map-
ing in the epicardium at the RVOT was very difficult. The
ggregated action potentials in the endocardium, epicar-
ium and midmyocardium could cause an averaging effect
hat prolongs ARI and RT and mask marked shortening of
epolarization.
The number of control subjects examined in this study
as relatively small. However, because type 1 ECG was not
bserved before and after pilsicainide administration in any
f the control subjects and since the main purpose of this
tudy was to investigate the relationship between appear-
nce of type 1 ECG and alteration of action potential in
atients with BrS, a large number of control subjects was
ot necessary in this study.
Because recent studies have shown that pilsicainide also
locked the K channel current of the human ether-a-go-
o-related gene (HERG) and could cause QT prolongation,
e could not completely exclude the possibility that pilsic-
inide administration directly prolonged action potential
uration in the epicardium (27).
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